Intrathecal Colistin and Intravenous Fosfomycin as a Combination Therapy for the Treatment of Acinetobacter Baumannii Ventriculitis and Meningitis

Bikash Khadka MD1, Saroj Poudel PharmD2

1Department of Anesthesiology and Critical Care, Nepal Mediciti, Lalitpur, Nepal
2Clinical Pharmacist, Nepal Mediciti, Lalitpur, Nepal

Date of submission: 6th June 2021 Date of acceptance: 22nd October 2021 Date of publication: 1st December 2021

Abstract
Treatment of central nervous system infection may be troublesome due to multidrug resistance. Colistin is less successful as a treatment option due to poor central nervous system penetration when used intravenously. We present the successful management of a case with ventriculitis and meningitis due to multidrug resistant Acinetobacter baumannii species with the combined intraventricular administration of colistin and intravenous fosfomycin after the initial regimen of colistin given alone through both intravenous and intrathecal routes had failed.

Key words: Acinetobacter baumannii, Colistin, Fosfomycin, Intrathecal, Multidrug resistant.

Introduction
Central nervous system (CNS) infections such as meningitis, ventriculitis, empyema and brain abscesses are extremely serious and difficult to treat. Neurosurgical interventions (craniotomy or ventriculostomy placement), craniocerebral trauma and invasive neuromonitoring techniques may also cause CNS infections. A recent retrospective study found an overall meningitis rate of 1.52% in 6,243 subjects undergoing craniotomy.1 CNS infections necessitate immediate and well-targeted treatment as it has high risk of neurological and systemic complications.

Acinetobacter baumannii is a gram-negative coccobacillus that can cause bacteremia, pneumonia, urinary tract infections and surgical wound infections. Meningitis is a rare but serious condition caused by acinetobacter infection, most commonly seen following the insertion of an indwelling ventriculostomy catheter, cerebrospinal fluid (CSF) leakage or head trauma. CNS infection associated with Acinetobacter baumannii has an incidence of 3.6 to 11%.2 Physical barriers and physicochemical properties of the antimicrobial agents have an influence on the drug distribution into the CNS. The tight junctions within the blood brain barrier (BBB) and blood-CSF barrier limit the diffusion of large molecular weight substances (500 Daltons). Antimicrobial agents with larger molecular weights (e.g. vancomycin or amphotericin B) have limited ability to penetrate an intact barrier. The pH of blood, CSF and extracellular fluid can change with infection and this can influence the polarity and hence anti-infective penetration of the CNS.3 Antibiotics such as aminoglycosides, glycopeptides and polymyxins have a very low therapeutic index with low CSF concentrations and therefore require lumbar, intrathecal (IT) or intraventricular (IVT) administration.4 The ventricles can act as a persistent reservoir of infection and inflammation, resulting in extreme difficulty in eradicating infection and potential blockade of CSF outflow tracts.5 Intraventricular and intrathecal administration of antibiotics may be necessary to overcome these difficulties.

We present a case of multiple drug resistant Acinetobacter baumannii post surgical meningitis that was successfully treated with high doses of fosfomycin combined with intrathecal colistin.
A 22-year-old man was admitted to the intensive care unit of our institute with a serious injury to his face and head with initial loss of consciousness following a bike accident. On neurological examination, he had a wound over the forehead with CSF. The cranial and cervical computed tomography (CT) scans revealed bifrontal contusion, a left temporal intracerebral hematoma with findings shown in figure 1 below. The patient underwent immediate decompression craniectomy and repair of the anterior cranial fossa. The patient was empirically treated with ceftriaxone (1g IV every 12 h) and vancomycin (1g IV every 12 h) because of high total lymphocyte counts (TLC of 14180) and persistent fever (38.3°C).

Due to persistent fever and signs and symptoms of raised intracranial pressure on 10th post-operative day, external ventricular drainage (EVD) was inserted and CSF analysis was done. CSF analysis showed it was turbid in appearance, watery, WBC count of 280 cells/mm3 (polymorphonuclear neutrophils 95 %), lymphocytes 5 %), glucose level <20 mmol/l, protein 3 g/l and Acinetobacter baumannii organism growth in culture. Antimicrobial susceptibility showed the strain was resistant to cephalosporins, beta-lactam, carbapenem and aminoglycosides but susceptible to tigecycline, colistin, Polymyxin-B (PMB) and ofloxacin. Following multidisciplinary team discussion, the patient was put under intraventricular colistin via EVD because of low CSF penetration of parenterally administered tigecycline and PMB. (colistin methanesulfonate (CMS) dosing: 10mg IVT per day and EVD clamp for 2 hours post colistin administration). Note: 1 vial = 1 million units = 80 mg (1 vial diluted with 8ml 0.9% normal saline = 1ml/10mg).

Before CMS administration, 5ml of CSF was aspirated and discarded (to avoid an increase of intracranial pressure induced by the bolus of CMS). After CMS administration, the ventricular drainage was flushed immediately with 2ml of saline solution to minimize the dose remaining in the drainage. The CMS was injected and the CSF samples were collected under sterile conditions and disinfected with chlorhexidine. The EVD was kept closed for at least 60-120 minutes.

On the 14th postoperative day, CSF analysis was repeated which showed turbid appearance, WBC count of 318 cells/mm3 and growth of Acinetobacter baumannii. Antimicrobial susceptibility was determined and the strain was now resistant to ofloxacin which was stopped and sulfamethoxazole/trimethoprim was added as per susceptibility.

Even after 7 days (17th day of illness) of intraventricular colistin treatment, the patient’s clinical status did not improve. Repeat CSF analysis showed turbid appearance, WBC count of 5800 cells/mm3 and Acinetobacter baumannii growth in culture. We planned for parenteral CMS (9 million units loading dose followed by 3 million units every 8 hours (As CSF penetration of CMS is more than 25%)) administration in place of IVT. As colistin monotherapy shows treatment failure, a high dose of parenteral Chloramphenicol (1 g every 6 h) was considered.

On the 27th day of illness, 10 days following IV CMS, 14 days for oral sulfamethoxazole/trimethoprim and 5 days for IV chloramphenicol, CSF culture was repeated which again had growth of Acinetobacter baumannii as shown in table below. Chloramphenicol was stopped and as a salvage therapy for MDR gram-negative and gram-positive organism, IV fosfomycin was added following multi-disciplinary team discussion (4 g of IV fosfomycin as a loading dose followed by 4 g every 6 hours). As IV fosfomycin has been reported to cause electrolyte disturbance (Hypernatremia and hyperkalemia) dilution was made in D5W (4 g of fosfomycin was dissolved in 100ml D5W and infused over 4 hour’s interval).

After 48 hours of intravenous administration of fosfomycin (Day 29), persistent fever subsided and patient was hemodynamically stable. After 5 days of intravenous administration of fosfomycin, a repeated CSF culture was sent and a negative result was found (no organism was isolated in CSF). IV fosfomycin was continued for 5 more days. No adverse effects were observed during antibiotic therapy. Treatment for lower respiratory tract infection was continued in ICU for another week and was later planned for Lumboperitoneal shunt placement.

**Discussion**

Acinetobacter baumannii is responsible for 10% of all gram-negative meningitis and 4% of nosocomial meningitis. The high mortality rates observed in patients with A. baumannii meningitis can be attributed in part to therapeutic difficulties associated with frequent inadequate antibiotic therapy and increased bacterial resistance due to which infrequently used antibiotics have spurred into the markets like fosfomycin and Polymyxins.

**Colistin**

Intraventricular colistin administered as CMS (colistin methanesulfonate) is used for the treatment of CNS infections caused by pan-resistant gram-negative bacteria. Intravenous colistin alone does not provide CSF concentrations high enough to reach a MIC of 2 mcg/mL for multidrug resistant (MDR) Gram-negative rods and therefore topical administration is needed to support the treatment. Colistin diffusion from the CSF to the systemic circulation and the cerebral tissue and the elimination through the external efflux of CSF, in addition to the unpredictable amount of the CSF spontaneously drained...
Intrathecal Colistin and Fosfomycin for CNS Infection

Table 1: Serial CSF analysis findings. POD: post operative day TC: Total count RBC: red blood cells.

| Characters/Day | 16th POD | 27th POD | 34th POD | 40th POD | 47th POD |
|----------------|----------|----------|----------|----------|----------|
| Colour/ appearance | Yellowish/ Slight turbid | Reddish/ Turbid | Light Yellow | Light yellow | Light yellow |
| TC(cells/cumm) | 28600 | 5800 | 3280 | 65 | 200 |
| Neutrophil (%) | 98 | 100 | 93 | 00 | 5 |
| Lymphocyte (%) | 2 | 00 | 7 | 100 | 95 |
| Glucose(mg/dl) | <20 | <20 | <20 | 44 | 62 |
| Protein(mg/dl) | 714 | 495 | 594 | 373 | 565 |
| RBC(cells/cumm) | 27000 | 12800 | 1350 | 400 | 100 |
| Culture | Acinetobacter baumannii isolated | Acinetobacter baumannii isolated | Acinetobacter baumannii isolated | NO growth | NO growth |

Figure 1: Serial CT Scan head finding: (A) Post central frontal craniectomy with scalp swelling, with mild herniation of frontal lobe and minimal SDH. (B) Post craniectomy with pneumocephalus in right frontal lobe with EVD in situ, mild dilatation of lateral and third ventricles (after a week of Scan A) with the start of intravenous colistin and 5 days of intrathecal Colistin administration. (C) Post craniectomy status with dilated ventricles (after 12 days of Scan A) on iv colistin and before start of intravenous Fosfomycin. (D) Post craniectomy status with reduced mass effect and herniation of frontal lobe (after 4 weeks of Scan A), corresponding to completion of treatment of IV Fosfomycin.
through the EVD by the fluctuation of intracranial pressure showing its appropriateness for treatment and IT/IVT dose of 125,000 IU/day suggested by the IDSA guidelines, but optimal IT/IVT dose remains uncertain.

**Fosfomycin**

Fosfomycin (FOF) is a low molecular weight antibiotic that has bactericidal activity against both Gram-negative and Gram-positive bacteria and reported that minimum inhibitory concentration (MIC) against *A. baumannii* is very high. The administration of intravenous fosfomycin has recently been revised due to its favorable pharmacokinetic properties, high tissue penetration, even in deep-seated infections, and low toxicity. Because the permeability of cerebrospinal fluid increases when the meninges become inflamed, the concentration of fosfomycin in the CSF can nearly triple in the case of meningitis.

Carbapenems have excellent in vitro activity against *Acinetobacter baumannii* and have been shown to have significant clinical success rates in the treatment of *A. baumannii* meningitis. As a result, antimicrobial options are extremely limited. Polymyxins are often the only antibiotics that show in vitro activity against multi-resistant strains. Colistin is an old drug that was abandoned decades ago due to nephrotoxicity. Although its permeability to cerebrospinal fluid is poor, it has recently become a new option or gained interest for the treatment of multidrug-resistant *Acinetobacter baumannii*.

In these cases, the identification of synergisms between antibiotics is an important tool, both due to the lack of treatment options and the recommended combination therapy with certain antibiotics such as fosfomycin and polymyxins, to achieve a more effective therapeutic response.

There are guidelines available such as those by the Infectious Diseases Society of America (IDSA) in 2004 that suggested a daily IT dosage of 10 mg (125,000 IU). We also followed the same guideline for colistin administration. A cumulative dose above 1,750,000 IU of colistin found significantly higher microbial elimination over 72 h of treatment in the group of patients treated with a combination of the two drugs (90.7%) than in the group treated with colistin alone (58.1%). At the end of treatment, complete microbiological elimination occurred in 100% of patients receiving the combination therapy compared with only 81.2% of patients treated with colistin alone.

A recent in vivo study using FOF combined with colistin found significantly higher microbial elimination over 72 h of treatment in the group of patients treated with a combination of the two drugs (90.7%) than in the group treated with colistin alone (58.1%). At the end of treatment, complete microbiological elimination occurred in 100% of patients receiving the combination therapy compared with only 81.2% of patients treated with colistin alone.

Fosfomycin has been reported to show a 100% synergistic effect after combining with other antibacterial drugs. Fosfomycin prevents the first stage of the cell wall synthesis procedure, whereas other antibiotics (such as carbapenem, polymyxins) inhibit the final phase.
Conclusion

For multidrug resistant meningitis and ventriculitis, intraventricular colistin along with iv fosfomycin has proved to be effective and safe. This combination, compared to the single colistin intraventricular administration, resulted in quick microbiologic and clinical improvement and future studies may refine further knowledge about the safety of this “salvage treatment”.

Acknowledgment

I would like to thank Dr. Diptesh Aryal, ICU coordinator for his constant support and guidance.

Conflict of Interest: None
Source(s) of support: None

References

1. Korinek AM, Reina M, Boch AL, Rivera AO, De Bels D, Puybasset L. Prevention of external ventricular drain–related ventriculitis. Acta Neurochir (Wien). 2005;147(1):39-45; discussion -6.
2. Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009;9(4):245-55. https://doi.org/10.1016/s1473-3099(09)70055-6
3. Kearney BP, Aweeka FT. The penetration of anti-infectives into the central nervous system. Neurol Clin. 1999;17(4):883
4. Bargiacchi O, De Rosa FG. Intrathecal or intraventricular colistin: a review. Infez Med. 2016;24(1):3-11
5. Salmon JH. Ventriculitis complicating meningitis. Am J Dis Child. 1972;124(1):35-40.
6. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafaillidis Pl. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gramnegative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009;34:111–20. https://doi.org/10.1016/j.ijantimicag.2009.03.009
7. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-84. https://doi.org/10.1086/425368
8. Kühnen E, Pfeiffer G, Frenkel C. Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection. 1987;15(6):422-4. https://doi.org/10.1007/bf01647220
9. Dubrovskaya Y, Chen T, Scipione MR, Esaian D, Phillips MS, Papadopoulos, et al. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 2013;57:5394–7. https://doi.org/10.1128/aac.00510-13
10. Imberti R, Cusato M, Accetta G, Marinò V, Procaccio F, Del Gaudio A, et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. Antimicrob Agents Chemother. 2012;56(8):4416-21. https://doi.org/10.1128/aac.00231-12
11. Ziaka M, Markantonis SL, Fousteri M, Zygoulis P, Panidis D, Karvouniaris M, et al. Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. Antimicrob Agents Chemother. 2013;57(4):1938-40. https://doi.org/10.1128/aac.01461-12
12. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tunietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943-50. https://doi.org/10.1093/cid/cis588
13. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2014;58:5598–601 https://doi.org/10.1128/aac.02435-13
14. Menegucci TC, Albiero J, Migliorini LB, Alves JL, Viana GF, Mazucheli J, et al. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents. 2016;47(5):380-5. https://doi.org/10.1016/j.ijantimicag.2016.02.007
15. Hashemian SMR, Farhadi Z, Farhadi T. Fosfomycin: the characteristics, activity, and use in critical care. Ther Clin Risk Manag. 2019;15:525-530. https://doi.org/10.2147/TCRM.S199119